Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | CNR2 | P34972 | 1/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.51 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9718643 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL3257919 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL9718660 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL4199161 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2782935 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL9718817 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL9456741 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL2782946 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL4094364 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 | |
| SCHEMBL4094354 | 0.92 | ALDH1A1 (0.60) | ALDH1A1CNR1CNR2LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067432-B2 | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-11-29 | — | — | US | claimed |
| US-20100221315-A1 | VESICULAR FORMULATIONS CONTAINING ORGANIC ACID PRODRUGS, PROCESS FOR THEIR PREPARATION | UNIVERSIDADE DE LISBOA (PT) | 2010-09-02 | — | — | US | claimed |
| US-20090246268-A1 | LIPOSOMAL, RING-OPENED CAMPTOTHECINS WITH PROLONGED, SITE-SPECIFIC DELIVERY OF ACTIVE DRUG TO SOLID TUMORS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2009-10-01 | — | — | US | claimed |
| EP-1257197-A4 | METHOD FOR TRANSDERMAL SAMPLING OF ANALYTES | HEALTH RESEARCH INC (US) | 2008-07-16 | — | — | EP | claimed |
| US-20080131497-A1 | Formulations of DNase and Methods of Use Thereof | TRANSAVE, INC. | 2008-06-05 | — | — | US | claimed |
| WO-2008039989-A2 | FORMULATIONS OF DNASE AND METHODS OF USE THEREOF | TRANSAVE, INC. (US) | 2008-04-03 | — | — | WO | claimed |
| EP-1819715-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | Neopharm, Inc. (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006052906-A2 | SYNTHESIS OF CARDIOLIPIN ANALOGUES AND USES THEREOF | NEOPHARM, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | claimed |
| EP-1556392-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | Neopharm, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1513853-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | Neopharm, Inc. (US) | 2005-03-16 | — | — | EP | claimed |
| WO-2004062569-A2 | CARDIOLIPIN COMPOSITIONS THEIR METHODS OF PREPARATION AND USE | NEOPHARM, INC. (US) | 2004-07-29 | — | — | WO | claimed |
| WO-2004039817-A9 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM INC (US) | 2004-07-22 | — | — | WO | claimed |
| WO-2004039817-A1 | CARDIOLIPIN MOLECULES AND METHOD OF SYNTHESIS | NEOPHARM, INC. (US) | 2004-05-13 | — | — | WO | claimed |
| WO-2003099830-A2 | CARDIOLIPIN COMPOSITIONS, METHODS OF PREPARATION AND USE | NEOPHARM, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1257197-A1 | METHOD FOR TRANSDERMAL SAMPLING OF ANALYTES | HEALTH RESEARCH, INC. (US) | 2002-11-20 | — | — | EP | claimed |
| US-6383138-B1 | Method for transdermal sampling of analytes | HEALTH RESEARCH, INC. | 2002-05-07 | — | — | US | claimed |
| WO-2001062144-A1 | METHOD FOR TRANSDERMAL SAMPLING OF ANALYTES | HEALTH RESEARCH, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| JP-8003068-A | — | — | None | — | — | JP | disclosed |
| EP-0037583-B1 | METHOD OF FLUOROMETRICALLY MEASURING THE ACTIVITY OF FAT-DEGRADING ENZYMES AND MEANS FOR CARRYING OUT THE METHOD | KSV-Chemicals Oy (FI) | 1984-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | ALDH1A1 4029/4885CNR1 984/4885CNR2 571/4885 |
| US-20080131497-A1 | Formulations of DNase and Methods of Use Thereof | DNASE1, DNASE1L3, ELANE | ALDH1A1 3645/4885CNR1 4567/4885CNR2 4469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.